PURPOSE: In prostate cancer, inactivating CDK12 mutations lead to gene fusion-induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS: We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 mutations. We used descriptive statistics to characterize their clinical features and therapeutic outcomes (prostate-specific antigen [PSA] responses, progression-free survival [PFS]) to various systemic therapies, including sensitivity to poly (ADP-ribose) polymerase and PD-1 inhibitors. RESULTS: Sixty men with at least monoallelic (51.7% biallelic) CDK12 alterations were identified across nine centers. Median age at diagnosis was 60.5 years; 71.7% and 28.3% were white and nonwhite, respectively; 93.3% had Gleason grade group 4-5; 15.4% had ductal/intraductal histology; 53.3% had metastases at diagnosis; and median PSA was 24.0 ng/mL. Of those who underwent primary androgen deprivation therapy for metastatic hormone-sensitive disease (n = 59), 79.7% had a PSA response, and median PFS was 12.3 months. Of those who received first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC; n = 34), 41.2% had a PSA response, and median PFS was 5.3 months. Of those who received a first taxane chemotherapy for mCRPC (n = 22), 31.8% had a PSA response, and median PFS was 3.8 months. Eleven men received a PARP inhibitor (olaparib [n = 10], rucaparib [n = 1]), and none had a PSA response (median PFS, 3.6 months). Nine men received a PD-1 inhibitor as fourth- to sixth-line systemic therapy (pembrolizumab [n = 5], nivolumab [n = 4]); 33.3% had a PSA response, and median PFS was 5.4 months. CONCLUSION: CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
PURPOSE: In prostate cancer, inactivating CDK12 mutations lead to gene fusion-induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS: We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 mutations. We used descriptive statistics to characterize their clinical features and therapeutic outcomes (prostate-specific antigen [PSA] responses, progression-free survival [PFS]) to various systemic therapies, including sensitivity to poly (ADP-ribose) polymerase and PD-1 inhibitors. RESULTS: Sixty men with at least monoallelic (51.7% biallelic) CDK12 alterations were identified across nine centers. Median age at diagnosis was 60.5 years; 71.7% and 28.3% were white and nonwhite, respectively; 93.3% had Gleason grade group 4-5; 15.4% had ductal/intraductal histology; 53.3% had metastases at diagnosis; and median PSA was 24.0 ng/mL. Of those who underwent primary androgen deprivation therapy for metastatic hormone-sensitive disease (n = 59), 79.7% had a PSA response, and median PFS was 12.3 months. Of those who received first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC; n = 34), 41.2% had a PSA response, and median PFS was 5.3 months. Of those who received a first taxane chemotherapy for mCRPC (n = 22), 31.8% had a PSA response, and median PFS was 3.8 months. Eleven men received a PARP inhibitor (olaparib [n = 10], rucaparib [n = 1]), and none had a PSA response (median PFS, 3.6 months). Nine men received a PD-1 inhibitor as fourth- to sixth-line systemic therapy (pembrolizumab [n = 5], nivolumab [n = 4]); 33.3% had a PSA response, and median PFS was 5.4 months. CONCLUSION:CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12deficiency in immunotherapy sensitivity.
Authors: Emmanuel S Antonarakis; Josep M Piulats; Marine Gross-Goupil; Jeffrey Goh; Kristiina Ojamaa; Christopher J Hoimes; Ulka Vaishampayan; Ranaan Berger; Ahmet Sezer; Tuomo Alanko; Ronald de Wit; Chunde Li; Aurelius Omlin; Giuseppe Procopio; Satoshi Fukasawa; Ken-Ichi Tabata; Se Hoon Park; Susan Feyerabend; Charles G Drake; Haiyan Wu; Ping Qiu; Jeri Kim; Christian Poehlein; Johann Sebastian de Bono Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Melissa A Reimers; Steven M Yip; Li Zhang; Marcin Cieslik; Mallika Dhawan; Bruce Montgomery; Alexander W Wyatt; Kim N Chi; Eric J Small; Arul M Chinnaiyan; Ajjai S Alva; Felix Y Feng; Jonathan Chou Journal: Eur Urol Date: 2019-10-20 Impact factor: 20.096
Authors: Mark M Pomerantz; Sandor Spisák; Li Jia; Angel M Cronin; Istvan Csabai; Elisa Ledet; A Oliver Sartor; Irene Rainville; Edward P O'Connor; Zachary T Herbert; Zoltan Szállási; William K Oh; Philip W Kantoff; Judy E Garber; Deborah Schrag; Adam S Kibel; Matthew L Freedman Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Ronald de Wit; Johann de Bono; Cora N Sternberg; Karim Fizazi; Bertrand Tombal; Christian Wülfing; Gero Kramer; Jean-Christophe Eymard; Aristotelis Bamias; Joan Carles; Roberto Iacovelli; Bohuslav Melichar; Ásgerður Sverrisdóttir; Christine Theodore; Susan Feyerabend; Carole Helissey; Ayse Ozatilgan; Christine Geffriaud-Ricouard; Daniel Castellano Journal: N Engl J Med Date: 2019-09-30 Impact factor: 91.245
Authors: Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan Journal: Cell Date: 2018-06-14 Impact factor: 41.582
Authors: Ilirjana Bajrami; Jessica R Frankum; Asha Konde; Rowan E Miller; Farah L Rehman; Rachel Brough; James Campbell; David Sims; Rumana Rafiq; Sean Hooper; Lina Chen; Iwanka Kozarewa; Ioannis Assiotis; Kerry Fenwick; Rachael Natrajan; Christopher J Lord; Alan Ashworth Journal: Cancer Res Date: 2013-11-15 Impact factor: 12.701
Authors: Pedro Barata; Elisa Ledet; Charlotte Manogue; Patrick Cotogno; Kendra Harris; Brian Lewis; Jodi Layton; Oliver Sartor Journal: Oncologist Date: 2020-07-12
Authors: Harsimar B Kaur; Thiago Vidotto; Adrianna A Mendes; Daniela C Salles; William B Isaacs; Emmanuel S Antonarakis; Tamara L Lotan Journal: Cancer Immunol Immunother Date: 2021-09-17 Impact factor: 6.630
Authors: Michael T Schweizer; Gavin Ha; Roman Gulati; Landon C Brown; Rana R McKay; Tanya Dorff; Anna C H Hoge; Jonathan Reichel; Pankaj Vats; Deepak Kilari; Vaibhav Patel; William K Oh; Arul Chinnaiyan; Colin C Pritchard; Andrew J Armstrong; R Bruce Montgomery; Ajjai Alva Journal: JCO Precis Oncol Date: 2020-04-21